Australian Rare Earths Limited (ASX:AR3) Completes $3.6M Rights Issue
Australian Rare Earths Limited (ASX:AR3) completes a $3.6M rights issue, enhancing project development and strategic positioning.
Tag: Industry-Specific News
Starpharma (ASX:SPL) Announces Q3 FY25 Activities Report
Starpharma (ASX:SPL) announces Q3 FY25 report with advancements in partnerships, product launches, and financial performance.
Linius Technologies Limited (ASX:LNU) Unveils Strategic Restructuring and Revenue Growth Plans
Linius Technologies (ASX:LNU) restructures operations and launches a new revenue pipeline aiming for breakeven by June 2026.
InteliCare Holdings Ltd (ASX:ICR) Partners with mecwacare for AI Platform Trial at Trescowthick Centre
InteliCare Holdings Ltd (ASX:ICR) partners with mecwacare to trial its AI-driven platform at Trescowthick Centre, enhancing aged care services in Victoria.
Australian Rare Earths Limited (ASX:AR3) Announces Uranium Exploration Results
Australian Rare Earths Limited (ASX:AR3) extends uranium mineralisation at Overland Project, supporting calcrete-hosted model with assay results expected soon.
Zelira Therapeutics Ltd (ASX:ZLD) Boosts Financial Flexibility with R&D Refund and ATM Facility
Zelira Therapeutics (ASX:ZLD) enhances financial flexibility with a $1.15M R&D refund and a $1M ATM facility to support ongoing developments.
Rimfire Pacific Mining (ASX:RIM) Reports Q1 Drilling Success and Raises $3.65M
Rimfire Pacific Mining (ASX:RIM) announces successful Q1 scandium drilling at Murga and Currajong, and raises $3.65M in funding.
Odyssey Gold Limited (ASX:ODY) Commences Technical Study for Tuckanarra Project
Odyssey Gold Limited (ASX:ODY) has launched a Technical Study to evaluate mining and processing options for its Tuckanarra Gold Project.
Immutep Limited (ASX:IMM) Reports Q3 FY25 Milestones and Financial Position
Immutep Limited (ASX:IMM) announces significant clinical trial milestones and maintains a robust cash position in its Q3 FY25 report.
Radiopharm Theranostics (ASX:RAD) Begins Phase 2b U.S. Trial for 18F-RAD101
Radiopharm Theranostics (ASX:RAD) initiates Phase 2b U.S. trial of 18F-RAD101, advancing diagnostic capabilities for brain metastasis.